Table 1. Patients’ characteristics.
| Wel/Mod | Por/Muc/Sig | p value | |
|---|---|---|---|
| (n = 1031) | (n = 120) | ||
| Age in years, median (IQR) | 69 (66–77) | 70 (60–77) | 0.68 |
| Sex, n (%) | |||
| Male | 646 (62.7%) | 65 (54.2%) | 0.070 |
| Female | 385 (37.3%) | 55 (45.8%) | |
| CCI, n (%) | |||
| 0 | 534 (51.8%) | 76 (63.3%) | 0.055 |
| 1, 2 | 393 (38.1%) | 34 (28.3%) | |
| ≥3 | 104 (10.1%) | 10 (8.3%) | |
| Barthel index, n (%) | |||
| 100 | 679 (65.9%) | 74 (61.7%) | 0.34 |
| 99–91 | 12 (1.2%) | 0 (0.0%) | |
| 90–61 | 68 (6.6%) | 13 (10.8%) | |
| 60–21 | 67 (6.5%) | 8 (6.7%) | |
| 20–0 | 66 (6.4%) | 7 (5.8%) | |
| Unknown | 139 (13.5%) | 18 (15.0%) | |
| Symptom of primary site, n (%) | |||
| None | 380 (36.9%) | 49 (40.8%) | 0.39 |
| Obstruction | 564 (54.7%) | 59 (49.2%) | 0.36 |
| Bleeding | 112 (10.9%) | 12 (10.0%) | 0.76 |
| Perforation | 34 (3.3%) | 6 (5.0%) | 0.53 |
| Primary site, n (%) | |||
| RCC | 340 (33.0%) | 67 (55.8%) | <0.001 |
| LCC | 435 (42.2%) | 29 (24.2%) | |
| Rectal cancer | 242 (23.5%) | 21 (17.5%) | |
| Unknown | 14 (1.4%) | 3 (2.5%) | |
| T-stage, n (%) | |||
| T1・T2 | 32 (3.1%) | 1 (0.8%) | 0.025 |
| T3 | 330 (32.0%) | 26 (21.7%) | |
| T4a | 472 (45.8%) | 61 (50.8%) | |
| T4b | 197 (19.1%) | 32 (26.7%) | |
| N-stage, n (%) | |||
| N0 | 164 (15.9%) | 5 (4.2%) | <0.001 |
| N1 | 352 (34.1%) | 37 (30.8%) | |
| N2 | 515 (50.0%) | 78 (65.0%) | |
| Number of metastatic organ, n (%) | |||
| 1 | 629 (61.0%) | 60 (50.0%) | 0.066 |
| 2 | 264 (25.6%) | 39 (32.5%) | |
| ≥3 | 138 (13.4%) | 21 (17.5%) | |
| Primary tumor resection, n (%) | 693 (67.2%) | 78 (65.0%) | 0.63 |
| Metastasectomy, n (%) | 200 (19.4%) | 12 (10.0%) | 0.006 |
| 1st line Chemotherapy, n (%) | |||
| Total | 778 (75.5%) | 75 (62.5%) | 0.002 |
| Doublet chemotherapy | 561 (54.4%) | 54 (45.0%) | 0.032 |
| Cytotoxic agents | |||
| Oxaliplatine | 538 (52.2%) | 52 (43.3%) | 0.15 |
| Irinotecan | 23 (2.2%) | 2 (1.7%) | |
| Molecular targeted therapy | |||
| None | 236 (22.9%) | 19 (15.8%) | 0.86 |
| VEGF | 282 (27.3%) | 30 (25.0%) | |
| EGFR | 43 (4.2%) | 5 (4.2%) | |
| 2nd line Chemotherapy, n (%) | |||
| Total | 543 (52.7%) | 50 (41.7%) | 0.026 |
| Cytotoxic agents | |||
| Others | 114 (11.1%) | 11 (9.2%) | 0.17 |
| Oxaliplatine | 176 (17.1%) | 15 (12.5%) | |
| Irinotecan | 253 (24.5%) | 24 (20.0%) | |
| 3rd line Chemotherapy, n (%) | |||
| Total | 319 (30.9%) | 28 (23.3%) | 0.09 |
| Cytotoxic agents | |||
| Others | 99 (9.6%) | 5 (4.2%) | 0.19 |
| Oxaliplatine | 71 (6.9%) | 7 (5.8%) | |
| Irinotecan | 149 (14.4%) | 16 (13.3%) | |
| 1st line period of doublet chemotherapy, days, median (IQR) | 148 (73–235) | 135.5 (70–248) | 0.55 |
| Best supportive care, n (%) | 235 (22.8%) | 43 (35.8%) | 0.002 |
Abbreviations: IQR = interquartile range; CCI = charlson comorbidity index; RCC = right colon cancer; LCC = left colon cancer; VEGF = vascular endothelial growth factor; EGFR = epidermal growth factor receptor.